MARYVILLE, Tenn. – (Sept 17, 2015) – Geneuity and Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The new panels will address Lung, Colon, Melanoma and an unknown primary 8 gene panel with soon to be released Gastrointestinal Stroma, Glioma, Ovarian, Renal and Thyroid solid tumor panels. Geneuity will be making the QIAGEN Human Tumor Actionable Mutations Panel available for clinical trial studies.
Dr. Jamie Platt, Vice President of Genomic Solutions at Geneuity and Molecular Pathology Laboratory Network, Inc., evaluated the illumina TruSight® Tumor 15 and said the panel’s simplicity and ease of use makes it well-suited for translational labs, “The value and appeal of next-generation sequencing is the potential to consolidate traditionally iterative tumor analyses. Our evaluation of the new TruSight Tumor 15, with its streamlined library prep and sequencing workflow, gives us confidence that this application is ideal for deployment. Even our most challenging samples produced results, including those with low nucleic acid inputs, giving us assurance we can analyze our most precious specimens.”
Geneuity CRS and Molecular Pathology Laboratory Network Inc. Vice President Genomic Solutions Jamie Platt Ph.D., will be presenting at the Thermofisher Ion Torrent Applications and Innovations Tour 2015 University of Tennessee Health Science Center Memphis TN. Sep 10th. and then in Atlanta GA. Sep 17th. Dr. Platt will present Targeted Gene Panels for Oncology Research.
Geneuity CRS and Molecular Pathology Laboratory Network Inc. Vice President Genomic Solutions Jamie Platt Ph.D., will be presenting at San Diego illumina Medical Genomics Summit June 8th 2015. Dr. Platt will present “LDTs to NGS IVD Systems, a Customers Perspective” and discuss verification of the first FDA IVD use cleared MiSeqDx Next Generation Sequencing system. Dr. Platt will also highlight differences between Laboratory Developed Tests (LDT) and IVD assays in a CLIA environment and share experiences with the illumina IVD assay Cystic Fibrosis 139-Variant Assay (IVD).
Geneuity CRS and Molecular Pathology Laboratory Network Inc. Vice President Genomic Solutions Jamie Platt Ph.D., will be presenting at Biomarkers & Diagnostics World Congress 2015 in Philadelphia PA. May 7th . Dr. Platt will present on ‘Opportunities and Challenges for NGS-Based Clinical Trials’. Key challenges in NGS-based clinical trials will be discussed, and opportunities around assay validation, companion diagnostics, data analysis, genomic annotation and supporting services will be highlighted.
Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) acquires the Illumina MiSeqDx™ next generation sequencing system to expand its portfolio of molecular testing and clinical research services to support growing demand in personalized medicine. Continue Reading…